Gossamer Bio Inc (NASDAQ:GOSS) major shareholder Fund V. Gp L.P. Omega sold 112,776 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $21.22, for a total transaction of $2,393,106.72. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
GOSS opened at $20.75 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 17.80 and a quick ratio of 17.80. The company has a market cap of $1.41 billion and a price-to-earnings ratio of -0.92. The firm has a 50 day simple moving average of $19.65 and a 200 day simple moving average of $19.76. Gossamer Bio Inc has a fifty-two week low of $15.59 and a fifty-two week high of $25.06.
Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.18). As a group, analysts expect that Gossamer Bio Inc will post -2.93 EPS for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of Montreal Can bought a new stake in shares of Gossamer Bio during the first quarter worth approximately $25,000. BNP Paribas Arbitrage SA bought a new stake in shares of Gossamer Bio during the second quarter worth approximately $42,000. JPMorgan Chase & Co. raised its stake in shares of Gossamer Bio by 87.5% during the second quarter. JPMorgan Chase & Co. now owns 5,995 shares of the company’s stock worth $126,000 after buying an additional 2,798 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Gossamer Bio by 39.3% during the second quarter. Royal Bank of Canada now owns 6,967 shares of the company’s stock worth $154,000 after buying an additional 1,967 shares during the last quarter. Finally, Rhumbline Advisers bought a new stake in shares of Gossamer Bio during the first quarter worth approximately $271,000. 54.64% of the stock is owned by institutional investors and hedge funds.
Gossamer Bio Company Profile
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.
Featured Story: Arbitrage
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.